Table 1. Characteristics of patient samples.

Patients no.	Age (years)	Gender	FAB subtype	Cell count (× 109/l)			Blast (%)		LDH value (U/l)	Extramedullary infiltration	Karyotype	Molecular features
				WBC	HB	PLT	PB	BM
1	38	M	M1	78.53	117	168	90	90.5	229.9	N	NA	–
2a	58	F	M4	14.49	106	64	26	44.5	551.6	N	46,XX; del(11)(q23)	–
3b	41	M	M2	51.35	87	26	88	89	104	N	NA	P53
4b	49	F	M5	75.85	103	40	72	77.5	923.6	N	46, XX	NMP1
5b,a	52	F	M2	29.43	95	52	46	61.5	1714	N	46,XX,t(8,21)(q22;q22)	AML1/ETO
6	57	M	M5	83.37	60	60	47	60.5	540	N	46, XY	–
7c	57	F	MDS/AML	2.03	74	42	23	30	126	N	46, XX	AML1/ETO; IDH2; RUNX1; SRSF2
8c	66	F	MDS/AML	127.68	61	58	46	70.5	787	Y	46, XX	P53; ASXL1; NOTCH1; RNRAS; RUNX1;PTPN11
9	23	M	M2	92.24	136	66	84	68.5	731.8	Y	46, XY	–
10	59	F	M2	31.43	76	96	70	69	1416	N	46, XX	–
11b	27	F	M2	4.33	89	15	24	38.5	247	N	46,XX,t(8,21)(q22;q22)	AML1/ETO
12c	58	M	MDS/AML	94.81	53	57	44	36	550	Y	46, XY	DNMT3A; RUNX1;SRSF2
13	66	M	M5	328.76	46	35	81	87.5	1096	NA	NA	NA
14	34	F	M1	15.5	66	20	78	84	358	Y	NA	–
15d	26	M	M2	25.32	146	122	84	73.5	357	Y	47, XY, +8	EVI1
16d	52	M	M5	97.3	72	108	57	61.5	140	N	46, XY	HOX11; NPM1
17d	47	F	M2	12.81	64	315	40	26.5	153.3	N	46, XX	AML1/ETO

Abbreviations: BM, bone marrow; F, female; FAB, French–American–British; HB, hemoglobin; LDH, lactic dehydrogenase; M, male; PB, peripheral blood; PLT, platelet; WBC, white blood cell.

^aSamples used for western blotting.

^bSamples used for detection of ROS.

^cPatients with secondary acute myeloid leukemia (sAML) derived from myelodysplastic syndromes (MDS).

^dSamples used for detection of clonogenicity ability.